+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID05117125

Study of Biomarkers for Predicting and Diagnosing Ventilator-Associated Pneumonia in ICU Patients on Mechanical Ventilation

Led by Region Skane · Updated on 2026-06-26

1000

Participants Needed

5

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate various peptide biomarkers, changes in the lung microbiome, and bacterial transcriptome patterns as possible tools to predict or diagnose ventilator-associated pneumonia VAP. The study focuses on understanding how these markers can help identify VAP in patients who are mechanically ventilated in intensive care units. Participants are grouped based on their VAP status those who fully meet VAP criteria, those showing signs of VAP but missing some variables like radiographic or microbiological findings, and those who do not develop VAP. The study evaluates several diagnostic tests including heparin-binding protein, interleukin-26, the lung microbiome, bacterial transcriptome, and proteome collected from mini-bronchoalveolar lavage samples. During the study, researchers collect samples and data at multiple time points Day 1, 3, 7, 14 depending on the participant group to measure changes in biomarkers over time. They assess microbiome diversity and bacterial transcriptome patterns as secondary outcomes. Participants are observed while receiving standard ICU care, with no experimental treatment given. The study will continue until the end of 2028, with primary outcome data expected by the end of 2026.

CONDITIONS

Brief Title

Biomarkers for Ventilator-associated Pneumonia

Research Team

M

Magnus Paulsson, PhD MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here